Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa”
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19837 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Fabrizio Martora und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Adalimumab, Rifampin, Clindamycin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Zitieren
APA
Martora, F., Potestio, L., Battista, T., & Megna, M. (2024). Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa”. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19837
Vancouver
Martora F, Potestio L, Battista T, Megna M. Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa”. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19837
BibTeX
@article{Martora2024,
author = {Martora, Fabrizio and Potestio, Luca and Battista, Teresa and Megna, Matteo},
title = {Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa”},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19837}
}
EUVIMED